GenoMed Welcomes Dame Shirley Bassey as Its First Patron

ST. LOUIS—June 12, 2007—GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced that Dame Shirley Bassey has agreed to become the company’s first Patron.

Dame Shirley, Britain's most successful female singer, is perhaps best known in the United States for “Goldfinger,” the title song of the 1965 James Bond film. In 2003, Dame Shirley celebrated 50 years in show business with a CD, “Thank You For The Years,” a Top 20 album in Britain. In recognition of her long career, Ms. Bassey, who was born in Wales, was made a Dame Commander of the British Empire (the female equivalent of a Knighthood) in 1999 by Queen Elizabeth II.

Dame Shirley has been very active in charity, raising money for the Royal Welsh College of Music and Drama, and the Noah’s Ark Children’s Hospital Appeal in Britain.

Said GenoMed's CEO, David Moskowitz MD, "Dame Shirley, in my mind and in the minds of many, is actually a Queen. She embodies the human royalty of merit, talent, beauty, determination, and graceful aging. She represents the very best that is within us. By lending her name to GenoMed’s effort, Dame Shirley is signaling to the world that our mission of preventive molecular medicine reflects society's highest aspirations.”

Added Dr. Moskowitz, “Our Patrons receive no shares or money from the company. Like Dame Shirley, they are deservedly world-famous, and simply want to increase global awareness of GenoMed’s mission to delay disease and aging. We are extremely honored that Dame Shirley has agreed to be our first Patron. And we shall be naming additional Patrons from time to time.”

About GenoMed

GenoMed (www.genomed.com) believes it has found the major aging gene. The company has already published superior clinical outcomes for diabetes, high blood pressure, emphysema, West Nile virus encephalitis, pancreatic cancer, psoriasis, and sickle cell disease. Please contact Dr. Moskowitz at dwmoskowitz@genomed.com if you are interested in joining the company’s Clinical Outcomes Improvement Program (COIP®).

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.